Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $529.3 million.

  • Kiniksa Pharmaceuticals International's Cash & Current Investments rose 5116.22% to $529.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $529.3 million, marking a year-over-year increase of 5116.22%. This contributed to the annual value of $243.6 million for FY2024, which is 1805.29% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Cash & Current Investments stood at $529.3 million, which was up 5116.22% from $423.5 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cash & Current Investments peaked at $529.3 million during Q3 2025, and registered a low of $182.1 million during Q2 2022.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Cash & Current Investments had a median value of $283.8 million in 2021 and averaged $289.7 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 4418.59% in 2022, then surged by 5116.22% in 2025.
  • Kiniksa Pharmaceuticals International's Cash & Current Investments (Quarter) stood at $182.2 million in 2021, then rose by 4.61% to $190.6 million in 2022, then increased by 8.27% to $206.4 million in 2023, then grew by 18.05% to $243.6 million in 2024, then skyrocketed by 117.28% to $529.3 million in 2025.
  • Its last three reported values are $529.3 million in Q3 2025, $423.5 million for Q2 2025, and $379.5 million during Q1 2025.